<DOC>
	<DOCNO>NCT00995605</DOCNO>
	<brief_summary>The purpose study determine whether AMAP102 safe well tolerated human .</brief_summary>
	<brief_title>AMAP102 - Safety , Tolerability Pharmacokinetics Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . In Groups A , B , D , E F , subject male ethnic origin 18 65 year BMI 20.0 30.0 kg/m2 2 . In Group C , subject female ( nonchildbearing potential ) ethnic origin 18 65 year BMI 20.0 28.0 kg/m2 3 . For Group C , woman nonchildbearing potential , define surgically sterile postmenopausal , nonlactating negative serum pregnancy test 4 . Subjects must good health , determine medical history , physical examination , 12lead ECG clinical laboratory evaluation 5 . Subjects give write informed consent participate study abide study restriction 1 . Male subject willing use appropriate contraception time first dose 3 month final dose occasion 2 . Subjects receive prescribed systemic topical medication within 14 day first dose administration 3 . Subjects use nonprescribed systemic topical medication within 7 day first dose administration 4 . Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration 5 . Subjects still participate clinical study participate clinical study involve administration investigational drug past 3 month 6 . Subjects donate blood , plasma platelet month prior screen make donation two occasion within 12 month precede first dose administration 7 . Subjects significant history drug allergy determine Investigator 8 . Subjects clinically significant allergic disease determine Investigator 9 . Subjects supine blood pressure supine pulse rate high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 40 bpm , respectively 10 . Subjects consume 28 unit ( male ) 21 unit ( female ) alcohol per week significant history alcoholism drug/chemical abuse determine Investigator ( one unit alcohol equal Â½ pint [ 285 mL ] beer lager , one glass [ 125 mL ] wine , 1/6 gill [ 25 mL ] spirit ) 11 . Subjects smoke 10 cigarette equivalent tobacco per day 12 . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological major disorder determine Investigator 13 . Subjects clinically significant illness within 4 week start dose administration determine Investigator 14 . Subjects know serum hepatitis , carrier HBsAg hepatitis C antibody , positive result test HIV antibodies 15 . Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study , QTc ( b ) interval great 430 msec ( male ) great 450 msec ( female ) , 2nd 3rd degree Atrioventricular block , complete leave bundle branch block , complete right bundle branch block WolffParkinsonWhite Syndrome , define PR short 110 msec , confirm repeat ECG 16 . Subjects significant cardiac history ( e.g . heart failure , hypokalemia , long QT syndrome ) , significant history fainting , syncope family history sudden cardiac death 17 . Subjects , opinion Investigator , participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>